The Clonal Diversity of Peripheral B Cell Receptor Immune Repertoire Impaired by Residual Malignant B Cells Predicts Treatment Efficacy in B Cell Lymphoma Patients.

Although we observed a slight trend of dose-dependency as the higher population of malignant B cells gave rise to lower BCR IR diversity on day 12, however, the most significant drop in clonal diversity was from zero to 0.001% tumor cells at the same time point.

also in 4,078 other papers